Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Multi Cancer Early Detection Market In 2029?
The size of the multi cancer early detection market has seen a quick expansion in recent years. There will be an increase from $1.45 billion in 2024 to $1.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 19.3%. Factors such as an increase in cancer prevalence, governmental initiatives and funding, amplified awareness of early cancer detection, the expansion of the healthcare infrastructure, the rise in the utilization of personalized medicine, and the decrease in genetic testing costs have all played a part in the growth during the historic period.
What Growth Rate Is Forecasted for the Multi Cancer Early Detection Market by 2029?
The market for early detection of multiple cancers is predicted to experience swift expansion in the coming years, ballooning to a value of $3.49 billion in 2029, with a compound annual growth rate (CAGR) of 19.1%. This projected growth within the timescale can be linked to the broadening reach of telemedicine and digital health, greater focus on preventive healthcare, rising use of precision oncology, advancements in the identification of biomarkers, and an uptick in direct-to-consumer genetic testing. Expected trends over this forecast period encompass a growing use of artificial intelligence and machine learning, increased preference for liquid biopsy techniques, the amalgamation of multi-omics methods, the spread of at-home testing kits, a heightened emphasis on preliminary cancer detection, and the emergence of minimally invasive diagnostic tools.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15864&type=smp
Which Key Companies Are Shaping the Future of the Multi Cancer Early Detection Market?
Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc., Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd., Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd., Singlera Genomics Incorporated, Naveris Inc., Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd., CanSense Ltd., Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx
Which Factors Are Driving Demand in the Multi Cancer Early Detection Industry?
The growth of the multi-cancer early detection market is set to be driven by an escalating shift towards personalized medicine. This approach to healthcare personalizes treatment and medical decisions based on each patient’s unique characteristics, genetic makeup, and needs. The burgeoning demand for personalized medicine is attributed to its ability to deliver improved treatment efficacy, a phenomenon backed by breakthroughs in genomics, the escalating complexity of diseases, and regulatory support. Customizing screening and treatment strategies according to individual genetic and biomarker profiles enhances the efficacy of multi-cancer early detection. As an illustration, the FDA gave approval to 16 new personalized therapies specifically for patients battling rare diseases in 2023, as per the data released by the US-based non-profit organization, Personalized Medicine Coalition, in February 2024. The figure was notably higher than the six authorized in 2022, with the recent approved therapies including seven drugs designed for cancer treatment and three aimed at various diseases and conditions. Thus, the emergence and rising preference for personalized medicine is fueling the growth of the multi-cancer early detection market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15864&type=smp
How Is the Multi Cancer Early Detection Market Segmented by Several Divisions?
The multi cancer early detection market covered in this report is segmented –
1) By Type: Liquid Biopsy, Gene Panel, Laboratory Developed Tests (LDT), Other Types
2) By Cancer Type: Solid Tumors, Hematological Malignancies
3) By End-User: Hospitals, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Liquid Biopsy Types: Circulating Tumor Cells (CTC), Circulating Tumor DNA (Ctdna), Exosomes
2) By Gene Panel: DNA-Based Panels, RNA-Based Panels, Multi-Gene Panels
3) By Laboratory Developed Tests (LDT): PCR-Based Tests, Next-Generation Sequencing (NGS) Tests, Immunohistochemistry (IHC) Tests
4) By Other Types: Protein Biomarkers, Autoantibody-Based Tests
What are the Emerging Market Trends Driving the Growth of the Multi Cancer Early Detection Industry?
Big corporations active in the multi-cancer early detection sector are creating ctDNA-based liquid biopsy tests to raise sensitivity, specificity, and early detection rates, which in turn boosts patient results. A ctDNA-based liquid biopsy test is designed to identify circulating tumor DNA in the bloodstream, offering a non-invasive way to track tumor progression, treatment responses, and minimal residual disease or early recurrence. For example, Lucence, a cancer diagnostics manufacturer from the United States, unveiled their innovative multi-cancer early detection (MCED) blood test, LucenceINSIGHT, at their US base in May 2023. This groundbreaking ctDNA-based liquid biopsy test facilitates screening for 10 common cancers using a single blood sample. Considering that 78% of global cancer fatalities happen from cancer types that lack regular screening recommendations, this blood test offers improved convenience and reachability for asymptomatic individuals who wish to get screened for a variety of cancers.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/multi-cancer-early-detection-global-market-report
Which Regions Are Driving Growth in the Multi Cancer Early Detection Market?
North America was the largest region in the multi cancer early detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15864
This Report Delivers Insight On:
1. How big is the multi cancer early detection market, and how is it changing globally?
2. Who are the major companies in the multi cancer early detection market, and how are they performing?
3. What are the key opportunities and risks in the multi cancer early detection market right now?
4. Which products or customer segments are growing the most in the multi cancer early detection market?
5. What factors are helping or slowing down the growth of the multi cancer early detection market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model